Abstract
purpose. To examine normal human corneal epithelium in vivo and in vitro for
expression and status of plasminogen activator inhibitor type 2
(PAI-2).
methods. Normal human corneas were prepared for frozen sections and for culture
of corneal keratinocytes. PAI-2 was analyzed by immunohistochemistry
and western blot analysis using antibodies that recognize all forms of
PAI-2.
results. In vivo and in vitro, PAI-2 was immunohistochemically localized to the
superficial corneal keratinocytes. Immunostaining also revealed the
presence of PAI-2 in its relaxed (i.e., cleaved) conformation. In vivo,
the staining pattern of the relaxed form was identical with that of
total PAI-2, but in vitro the relaxed form was detected in a smaller
subpopulation of superficial cells. In vitro, the staining pattern
indicated a cytoplasmic localization for PAI-2. Western blot analysis
revealed that most of the PAI-2 was cell associated and functionally
active.
conclusions. The present results are the first to show that PAI-2 is found in normal
human corneal epithelium in vivo and in vitro, where it can be
considered as a differentiation product. At least in vitro, all
detectable PAI-2 is cell associated, with a cytoplasmic distribution. A
subpopulation of keratinocytes also contains PAI-2 in its relaxed
(i.e., cleaved) conformation. Cleavage by an as yet unidentified
cytoplasmic proteinase may constitute a crucial aspect of the function
of corneal epithelial PAI-2, which may be relevant to terminal
differentiation and death of the corneal
keratinocyte.
Cells within the cornea and conjunctiva have the ability to
synthesize many proteinases and their inhibitors, which have been
implicated in physiological and pathologic ocular
processes.
1 2 One such proteolytic system is the
plasminogen activator (PA) cascade.
3 4 5 6 The PA system
consists of the serine proteinases urokinase plasminogen activator
(uPA) and tissue plasminogen activator (tPA), each of which converts
plasminogen to plasmin, a serine proteinase able to cleave many
extracellular matrix proteins, including its classic substrate
fibrin.
7 Several inhibitors in the class known as serine
proteinase inhibitors (serpins) regulate uPA and tPA. These include PA
inhibitors type 1 and type 2 (PAI-1 and PAI-2) and protease nexin
1.
8 The PA cascade has been implicated in many
physiological and pathologic events such as ovulation, inflammation,
wound repair, angiogenesis, neuronal plasticity, and
neoplasia.
7 9 10 11 12 13 Within epithelial tissues, uPA has been
associated with cell migration and proliferation, whereas tPA has been
correlated with differentiation.
14 15 16 17 18 19 20 21 PAI-2 (but not
PAI-1) has been detected constitutively in several normal murine and
human stratified squamous epithelia.
22 23 24 25 The high levels
of PAI-2 and its concentration in the superficial layers of stratified
squamous epithelia have led to the hypothesis that this inhibitor plays
a role during differentiation of at least some epithelia.
PAI-2 is a member of the ovalbumin family of serpins
26 and
was first identified in human placenta and
macrophages.
27 28 29 30 31 Although early reports suggest that
PAI-2 may have a very limited tissue distribution, it is now
appreciated that PAI-2 is present in stimulated human endothelial
cells,
32 cultured vascular smooth muscle
cells,
33 fibroblasts from fetal lung and
foreskin,
34 human gingival cervicular fluid and whole
saliva,
35 36 normal human epidermis and cultured
epidermal keratinocytes,
22 23 37 epithelial cells of the
murine hair follicle and nail apparatus,
24 and numerous
other stratified squamous epithelia.
25 PAI-2 has been
associated with pregnancy, inflammation, apoptosis, and epidermal
differentiation (reviewed in
Ref. 31) . In many cell types, including
the epidermal keratinocyte, a large proportion of PAI-2 is found in the
cytoplasm.
29 37 Given the vast evidence that both
plasminogen activators (the only known proteinase targets for PAI-2)
function extracellularly, the intracellular localization of PAI-2 is
very unexpected and raises the possibility that PAI-2 interacts with an
unidentified cytoplasmic proteinase.
Very recently, with the generation of a novel antibody,
38 it has become possible to detect PAI-2 that has previously interacted
with a proteinase as either a substrate or inhibitor in
vivo.
39 Similar to other serpins, PAI-2 contains an
exposed reactive loop near the C terminus which, on proteolytic
cleavage, is inserted into the central β-sheet of the inhibitor,
resulting in a conformational change to a stabilized, or relaxed,
state.
40 When PAI-2 interacts with target proteinase, the
inhibitor is cleaved in its reactive loop, a stable enzyme–inhibitor
complex is formed, and the proteinase is, for all practical purposes,
irreversibly inhibited. PAI-2 may also be cleaved by a proteinase that
rapidly escapes from the inhibitor after cleavage, thus retaining its
proteolytic activity while generating an inactive inhibitor; in this
case PAI-2 is acting not as an inhibitor but as a substrate. In either
case, the cleaved PAI-2 assumes a similar stabilized, that is, relaxed,
conformation. We have used an antibody that specifically detects a
conformational determinant unique to the relaxed form of
PAI-2
38 to examine the state of PAI-2 in human corneal
keratinocytes in vivo and in vitro. Our data show for the first time
not only that PAI-2 is synthesized by corneal keratinocytes, but also
that this inhibitor is constitutively cleaved by an endogenous corneal
proteinase.
Frozen sections (5 μm) of normal human cornea were fixed in
acetone for 20 minutes at −20°C. After washing in PBS and blocking
in PBS containing 10% normal horse serum, sections were incubated for
45 minutes at room temperature with 4 μg/ml primary antibody: mouse
monoclonal anti-human PAI-2 antibody (3750; American Diagnostica,
Greenwich, CT), which recognizes all known forms of PAI-2, or mouse
monoclonal anti-relaxed PAI-2 antibody 2H5, which is specific
for a conformational determinant found only on the relaxed form of
PAI-2 (produced and purified by Dr. Baker and Dr.
Saunders).
38 As negative controls, mouse monoclonal
antibodies against chlamydia antigen or hepatitis antigen were used.
After washing, sections were sequentially incubated with biotinylated
secondary horse anti-mouse IgG, avidin-biotin-peroxidase (Vector,
Burlingame, CA), and diaminobenzidine tetrahydrochloride substrate
(Sigma, St. Louis, MO).
Corneal keratinocyte cultures grown on glass coverslips were
immunohistochemically stained using similar procedures, except that
fixation and permeabilization were carried out by sequential treatments
with acetone and then methanol for 10 minutes each at −20°C. In some
experiments, detection was with the peroxidase method just described;
in other cases, fluorescein isothiocyanate (FITC)–labeled goat
anti-mouse secondary antibody (Pierce, Rockford, IL) was used.
In one series of experiments, we tested for the presence of PAI-2 on
the cell surface by incubating live cells with antibodies under
conditions in which internalization of immune complexes was blocked.
Briefly, cultures on coverslips were preincubated in medium containing
0.05% sodium azide for 30 minutes at 37°C and then incubated with
primary antibody on ice for 45 minutes. After washing, the cultures
were fixed in 1% paraformaldehyde at room temperature for 10 minutes,
blocked in PBS containing 10% normal goat serum and 0.1 M glycine (pH
7.6) and incubated with FITC-labeled goat anti-mouse IgG for 45
minutes. No staining was detectable on the cells using this method with
either anti-PAI-2 or anti-relaxed PAI-2 antibodies.